ArticleBMC complementary medicine and therapies2025
Marine actinobacterium Streptomyces vinaceusdrappus mediated nano-selenium: biosynthesis and biomedical activities.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Multi-targeted pyrazole scaffolds: synthesis, mechanistic insights, and therapeutic potential in anticancer, antioxidant, and anti-inflammatory applications.The Libyan journal of medicine · 2026Article
- BiogenicRSC advances · 2026Article
- Fagonia indica mediated biosynthesis of iron oxide nanoparticles with enhanced antimicrobial and therapeutic potential.Discover nano · 2026Article
- Bacterial metabolite-directed synthesis of biogenic TiORSC advances · 2026Article
- Multifunctional Se-Cu bimetallic nanoparticles from marineRSC advances · 2026Article
- Recent advances in the role of selenium and nanoselenium in modulating plant defense under biotic and abiotic stresses.Frontiers in plant science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiogenic Selenium nanoparticles (Se-NPs) have been receiving more attention, primarily due to their remarkable biomedical potential. This study was designed to biosynthesize Se-NPs using marine actinobacterium Streptomyces vinaceusdrappus AMG31 metabolites and comprehensively evaluate their multifunctional biomedical applications.
methodsThe actinobacterial biofabricated Se-NPs were characterized by UV-vis spectroscopy, FT-IR, XRD, TEM, EDX, DLS, and zeta potential. Se-NPs were then evaluated for their biomedical applications, including antioxidant (DPPH, ABTS, TAC, and FRAP assays), wound healing (scratch assay on HFB4 cell line), hemocompatibility, anticancer (crystal violet viability assay), antidiabetic (α-amylase and α-glucosidase inhibition), antimicrobial (agar well diffusion and MIC/MBC/MFC determination), antibiofilm, and anti-inflammatory properties (COX-enzymes in vitro inhibition).
resultsFormed Se-NPs exhibited crystalline, stable, and spherical structures with sizes ranging from 20 to 80 nm and a negative zeta potential of -37.9 mV. Se-NPs exhibited potent antioxidant activity, achieving 86.7% DPPH scavenging, 84.6% ABTS scavenging, a TAC value of 965.967 µg/mg ascorbic acid equivalent, and a FRAP value of 727.667 µg/mg ascorbic acid equivalent. Se-NPs promoted enhanced wound healing, with a wound closure percentage of 73.6% at 209.87 µg mL–1. Se-NPs displayed selective cytotoxicity towards Caco-2 (IC50 = 102.5 µg mL–1) and PANC-1 (IC50 = 100.4 µg mL–1) cancer cells while exhibiting minimal toxicity against normal WI-38 fibroblasts (IC50 = 419.7 µg mL–1). Furthermore, Se-NPs demonstrated concentration-dependent inhibition of α-amylase (IC50 = 59.8 µg mL–1) and α-glucosidase (IC50 = 19.3 µg mL–1), suggesting antidiabetic potential. Nano-selenium exhibited promising antifungal activity against Aspergillus niger (MIC = 25 µg mL–1, MFC = 200 µg mL–1), Penicillium glabrum (MIC = 50 µg mL–1, MFC = 200 µg mL–1), Mucor circinelloides (MIC = 100 µg mL–1, MFC = 300 µg mL–1), Trichoderma harzianum (MIC = 100 µg mL–1, MFC = 200 µg mL–1), and Candida albicans (MIC = 12.5 µg mL–1, MFC = 50 µg mL–1 and 95.4% biofilm inhibition). Moreover, nanostructure showed antibacterial activity most effectively against Enterococcus faecalis (MIC = 25 µg mL–1, MBC = 50 µg mL–1) and Pseudomonas aeruginosa (MIC = 50 µg mL–1, MBC = 50 µg mL–1) with over 90% inhibition of biofilm formation. Finally, the nano-selenium structure showed potent inhibitory action against COX-1 (IC50 = 30.9 µg mL–1) and COX-2 (IC50 = 46.6 µg mL–1).
conclusionThe obtained results confirmed the efficacy of marine actinobacterium S. vinaceusdrappus metabolites to fabricate Se-NPs which exhibits broad spectrum biomedical activities including antioxidant, anticancer, antidiabetics, antimicrobial, antibiofilm, anti-inflammatory, and wound healing activities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.